Introduction
Mesenchymal stromal cells' (MSCs), formerly known as mesenchymal stem cells, 1 denomination that has been replaced recently 2 because of their heterogeneous cell multipotency and fibroblastic-like properties, 3 are stromal progenitors endowed with multi-lineage differentiation potential toward mesodermal cell lineages 4, 5 and extensive immune-modulatory properties. 6 Three main criteria have been identified by the International Society of Cellular Therapy (ISCT) to define MSCs: (i) Adhesion to plastic, (ii) expression of specific immunophenotypic marker combinations (CD73, CD90 and CD105), and lack of expression of hematopoietic markers (CD14, CD34 and CD45) and class-II major histocompatibility complex (MHC) molecules; (iii) capability of differentiating into mesodermal lineages (adipocytes, osteoblasts and chondrocytes). 2 All cultured MSCs normally show these main biological features, but some differences may be observed among MSCs of different tissue origin, that is, expression of surface CD34 and CD54 by adipose-tissue-derived MSCs. 7 In addition, MSCs may show in vitro, under specific experimental conditions, some features of differentiation into tissues of endodermal and neuroectodermal lineages, such as hepatocytes, 8 epithelia 9 and neurons, 10, 11 but their nonmesodermal differentiation, both in vitro and in vivo, is still a matter of debate. 12, 13 The regulatory activity of MSCs has been described toward a large number of effector cells of adaptive and innate immunity, including T-cell subsets, B cells, NK cells, monocyte-derived dendritic cells and neutrophils. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] This property is expressed not only by bone marrow MSCs, but also by MSCs derived from other tissues, that is, fat, 25 thymus and spleen, 26 and also by MSC progeny, that is, adipocytes, osteoblasts 27, 28 and fibroblasts belonging to different tissue microenviroments. 3, 14, 29, 30 In particular, independently of their differentiation state and origin, fibroblasts and terminally differentiated mesenchymal cells prevent both proliferation and apoptosis of activated T cells, thus suggesting the potential in vivo physiological role of the immune regulation mediated by the stromal cell compartment derived from resident MSCs. 3, 14, 29, 30 A broad panel of molecular pathways is involved in MSC-mediated immune regulation, including interferon-g (IFN-g), 18, 26 interleukin-1b (IL-1b), 31 transforming growth factor-b1, 14, 27, 32 indoleamine-2,3-dioxygenase (IDO), 18, 26, 33 IL-6, 34,35 IL-10, 36,37 prostaglandin-E2, 38 hepatocyte growth factor, 14 tumor necrosis factor (TNF)-a, [39] [40] [41] nitric oxide (NO), 42 heme oxygenase-1, 43 HLA-G5, 44, 45 and many other factors, some of which are still unidentified. Apparently, there is not a unique and hierarchically prevalent mechanism responsible for MSC immune regulation; however, the redundant panel of multiple pathways, some of them reciprocally activating, eventually leads to the anergy of immune effector cells regardless their antigen-mediated activation, 3, and suggests that this property must be preserved for normal tissue homeostasis and interaction with immune effector cells infiltrating the tissues in the event of inflammation.
Actually, MSCs are not only immune-inhibitory cells, but under resting conditions they possess antiapoptotic and supporting properties toward different cells types such as hematopoietic stem cells, 46 T cells, 47 B-cell precursors, 48, 49 plasma cells 50 and neoplastic cells. [51] [52] [53] In addition, MSCs may act as antigenpresenting cells (APCs) and pro-inflammatory cells [54] [55] [56] (Figure 1) . Thus, the modulatory activity is not constitutively expressed by MSCs, but depends on a process of 'licensing' to be acquired. This term, far from dealing with the commercial use of MSCs, defines in one word the multistep process that leads to the functional maturation of MSCs and implies:
(1) 'Activation' of MSCs by means of inflammatory cytokines, such as IFN-g or tumor necrosis factor-a (TNF-a) and IL-1a/b, that are early produced by different cells as a consequence of antigen processing and immune effector cell activation; [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] (2) The prevalence of priming stimuli on MSC over signals that may hamper their inhibitory mechanisms, such as triggering of Toll-like receptors by infectious agents or endogenous danger signals; [71] [72] [73] [74] [75] [76] [77] [78] [79] (3) The timing of MSC engagement in the activation process of immune effector cells.
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MSC activation
A common finding of assays aimed to show the immunemodulatory properties of MSCs is that activation of effector cells, such as T cells, is required for the onset of the MSC-mediated inhibition of the effector cells themselves. One of the first cytokines to be produced following T-cell activation is IFN-g. This cytokine would normally act as a boost signal for T-cell activation and expansion, but in the presence of MSCs, IFN-g leads to the suppression of T-cell proliferation by triggering the inhibitory machinery of the MSCs themselves, as shown by the evidence that anti-IFN-g receptor-blocking antibodies can revert their inhibitory effect 57 and that IFN-g receptor-negative MSCs do not inhibit T cells. 59 Thus, IFN-g release and binding of IFN-g to its receptor expressed by MSCs 57 represent a pivotal 'licensing' step to induce MSC-mediated immunosuppression, not only toward T-cell subsets but also B cells, which are normally insensitive to MSCs in the absence of IFN-g, and NK cells. 57, 58 However, IFN-g concentration as well as simultaneous release of inflammatory cytokines are equally important factors in driving the polarization of MSCs. It has been shown that MSCs, under the effect of IFN-g, may behave not only as inhibitory cells but also as efficient APCs, leading to the induction of specific immune responses against different antigens, such as ovoalbumin and influenza virus. 54, 55 MSCs can even present extracellular antigens by MHC class-I instead of class-II, a property known as antigen cross-presentation and typical of dendritic cells, thus inducing specific CD8 þ T-cell immune responses. 56 What determines the different response to antigens seems to be the concentration of IFN-g: MSCs may act as APCs toward Candida albicans or Tetanum toxoid at low IFNg concentrations (19-25 pg/ml), whereas they may inhibit the specific response at higher doses. 54 This phenomenon is associated with the expression pattern on MSCs of MHC class-II molecules, whose downregulation correlates with the progressive acquisition of the inhibitory phenotype. 54 However, there is no concordance in the literature about concentrations of IFN-g required for an MSC shift from being APCs to showing inhibitory functions: in different sets of experiments, ng/ml concentrations of IFN-g 55 led to either acquisition of the same APC phenotype obtained with pg/ml concentrations, 54 or to the appearance of inhibitory properties, 57 thus questioning the real narrowness of the IFN-g dose window previously postulated. 54 It is likely that, also the duration of IFN-g priming, which is quite variable in the different experimental settings reported in the literature, may have a role in MSC polarization. However, it is difficult to translate these findings in the in vivo microenviroment, where local production of IFN-g cannot be measured; thus, the physiological role of MSCs as APCs, as well as inhibitory cells, remains unknown.
The other factor involved in MSC polarization toward displaying inhibitory functions is the release of inflammatory cytokines such as TNF-a, IL-1a or IL-1b, which are all unable, when used as single agents, to trigger the MSC-mediated inhibition of T-cell proliferation. 59 However, the combination of IFN-g with one of the other cytokines strongly enhances the inhibitory effect of MSCs observed with IFN-g alone, which is then sufficient to activate the MSCs. 59 The addition of blocking antibodies against all the four cytokines, but not against the single molecules, completely reverts the inhibition of T-cell proliferation in a greater manner than with anti-IFN-g alone. 59 The MSC immunophenotype is dramatically modified by TNF-a or IL-1a/b through the induction of MHC class-I, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 upregulation, 60 and the de novo expression of not only MHC class-II, which would theoretically favor their APC functions, but also the inhibitor ligand B7-H1 (PD-L1).
59,61,62 IFN-g in combination with TNF-a promotes IL-8, IL-6, 63 hepatocyte growth factor and prostaglandin-2production, and cyclooxygenase-2 activity, 64 whereas it may induce IDO and B7-H1 upregulation when used as single agent. 62, 64 Very recently it has been shown that the inflammatory priming of human MSCs, through the induction of cyclooxygenase-2, determines the downregulation of heme oxygenase-1 activity, thus preventing the inhibitory effects of MSCs, the induction of regulatory T cells and the promotion of IL-10 production for MSCs. 65 In addition, MSC priming with IFN-g plus TNF-a leads to the activation of superoxide dismutase 3, an anti-inflammatory enzyme involved in the catabolism of O 2 À that has 'scavenger' and protecting properties toward neurons, that is, a neuronal and axonal pro-survival effect against activated microglia-induced damages. 66 Furthermore, the IFN-g and TNF-a combination induces the production of chemokines such as CCR5, CCR10, 59 ,63 CXCL9, CXCL10 and CXCR3, 59 all involved in the chemotaxis and the inhibition immune effector cell proliferation. 59 Finally, IFN-g and TNF-a act synergistically in inducing NO production through inducible nitric oxide synthase, a process necessary for T-cell inhibition in vitro and for the prevention of delayed-type hypersensitivity and graftversus-host disease (GvHD) in vivo. 59 Similarly to MSCs, differentiated stromal cells, such as synovial fibroblasts, as well require an activation step to exert their immune-regulatory properties, as shown indirectly by the evidence that only supernatants obtained from fibroblastactivated T-cell co-cultures may inhibit secondary cultures in which T cells are induced to proliferate. 3 However, the role of IFN-g and IL-1 was not clearly demonstrated, as the presence of fibroblasts inhibited per se the percentage of IFN-g-producing cells, and addition of IL-1 receptor (IL-1RA) inhibitors to stimulated peripheral blood mononuclear cell cultures inhibited proliferation even in the absence of fibroblasts. 3 Similarly, Wharton's jelly stromal cells show quite comparable inhibitory properties on lymphocytes to that of bone marrow MSCs, with some peculiarities related to cytokine profile and phenotypic changes, and require licensing by inflammatory cytokines such as IFN-g and TNF-a. 67, 68 This evidence suggests a general, major anti-inflammatory role for the stroma also during pregnancy. 67, 68 Most data concerning MSC activation have been obtained by studying either human or mouse MSCs. However, and quite importantly, there are some significant differences between mouse and human MSCs in terms of the molecular pathways triggered by inflammatory cytokines. For instance, it has been shown very recently that priming of human MSCs with inflammatory cytokines makes them acquire efficient antimicrobial activities against a number of pathogens such as 69 IDO appears clearly to be involved in these mechanisms and its activity in human MSCs is modulated in a bimodal manner, driving the MSCs toward an antimicrobial rather than an inhibitory behavior on the basis of the kind of stimulus that causes the degree of tryptophan depletion. 69 Mouse MSCs neither express IDO nor inhibit bacterial growth: instead, only mouse MSCs, but not human MSCs, express inducible nitric oxide synthase. 69 These differences, besides uncovering species-related biological peculiarities of stem cells, question the reliability of mouse models in reproducing the immune-regulatory effects in vivo that are required for the clinical application of MSCs in humans.
The pivotal role of MSC activation may be shown also in vivo. MSCs pre-treated with IFN-g become immediately active and could suppress GvHD more efficiently than a five-fold-greater number of MSCs that were not activated; when administered at the time of a bone marrow transplant, activated MSCs can prevent mortality from GvHD (100% survival, P ¼ 0.006). 70 
Balancing among opposite stimuli on MSCs
The acquisition of immunosuppressive rather than immunostimulating properties by MSCs depends on a complex balance between stimuli of different origin, which may functionally polarize the MSCs. To this aim, an important role is played by Toll-like receptors (TLRs).
TLRs are a highly preserved family of non-catalytic receptors localized on the cell surface or in the cytoplasmic membrane system of most living species. TLRs recognize both molecules derived from microbes (pathogen-associated molecular patterns) and potential endogenous danger signals derived from cell death. TLRs are involved in the induction of prompt innate immune responses and in the preparation, through dendritic cells, of specific adaptive immune responses. 71 MSCs express TLR1, TLR2, TLR3, TLR4, TLR5 and TLR6 at the mRNA level; in addition, expression of TLR2, TLR3, TLR4, TLR7 and TLR9 at the protein level has been shown by flow cytometry. However, the expression of some TLRs may be regulated by various factors, including oxygen level. [72] [73] [74] [75] TLR triggering affects various biological properties of MSCs. TLR2 induces the production of IL-6 and proliferation, and inhibits osteo-/adipo-/chondrogenic differentiation but not immune modulation; TLR3 induces the migration and, similarly to TLR4, TLR5 and TLR9, the production of cytokine/chemokines such as IL-1b, IL-6, IL-8, IL-10, TNF-a and IL-12-p70; in adipose-derived MSCs, TLR2 induces cytokine/chemokine production, whereas TLR2 and TLR4 enhance osteoblastic differentiation and TLR9 inhibits proliferation. [72] [73] [74] [75] As far as immunological properties are concerned, the expression of TLR3 and TLR4 by MSCs is of particular interest. The binding of specific ligands to these TLRs (poly(I:C) for TL3 and lipopolysaccharide (LPS) for TLR4) may lead to the downregulation on of Jagged1on the surface of MSCs, which cannot bind anymore to the Notch1 expressed by T cells, thus interfering with MSC-mediated immune modulation. 75 In addition, MSC activation through TLR3 and TLR4 determines the induction of pro-inflammatory molecules such as IL-1, IL-6, IL-8, TNF-related apoptosis-inducing ligand (TRAIL) and CCL5, and the enhancement of inducible nitric oxide synthase activity, thus promoting the inflammatory response against pathogens. 76 However, the immunosuppressive activity of MSCs maybe even enhanced if TLR3 and TLR4 are triggered on MSCs before the co-culture with T cells. 77 On the basis of contradictory results in the literature, mainly owing to the use of different ligand concentrations and variable culture time, it has been hypothesized recently that MSC functions following TLR stimulation may vary according to activation kinetics, thus resembling the response of monocytes/ macrophages to TLR ligands. In fact, monocytes activated with specific cytokines (such as IFN-g) or TLR4 agonists (such as LPS) acquire the typical pro-inflammatory functions (M1 phenotype); by contrast, when primed with others cytokines, such as IL-4, monocytes are driven toward the acquisition of anti-inflammatory and tissue-repair functions (M2 phenotype). 78 It has been shown that even MSCs when their TLR3 or TLR4 are triggered shortly (1 h) with low doses of ligands, which are postulated to mimic the gradient of danger signals that endogenous MSCs encounter and respond to at a distance from the site of injury, may show the opposite functional polarization described for monocytes. 79 In particular, TLR4 priming leads MSCs to release mostly pro-inflammatory cytokines such as IL-6, IL-8, or transforming growth factor-b (MSC1 phenotype), leading to the activation of T cells when co-cultured with MSC1. By contrast, TLR3 priming leads MSCs to produce immunosuppressive molecules such as IL-4, IL-1RA, IDO and prostaglandin-2 (MSC2 phenotype), leading to the typical T-cell inhibition thoroughly described in the literature. 79 According to these findings, one could imagine that the same stimuli that drive monocyte functional polarization may also influence the response of the MSC-derived stromal cell compartment, with a cross-talk between the two cell systems and a time-dependent oscillation of their functional status, as a result of the concentration of the ligands involved and the progressive release of cytokines (Figure 2 ). However, it is difficult to translate this simplified model directly in vivo, as MSC polarization can be dramatically modified by longer exposure to TLR ligands and/or the simultaneous presence of different cytokines with opposite effects. 
Timing of MSC engagement
When the immune-regulatory properties of MSCs are studied in vivo, one of the most surprising findings is the discrepancy between the clinical effect observed, sometimes dramatic like in the case of acute GvHD, 80,81 sepsis 82 and acute renal failure, 83 and the virtually complete lack of long-term engraftment of transplanted MSCs inside the tissues involved in the damage, regardless of the evidence of histological improvement. [80] [81] [82] [83] In fact, the beneficial effect of MSCs after systemic administration seems to mainly rely on the secretion of soluble factors at the inflammation site, where MSCs become undetectable only a few days after their injection, rather than on cell persistence and proliferation. 83 Another significant point of interest is that, not always the beneficial effect of MSC infusion can be achieved in the same kind of disease, but it seems to depend on the timing of MSC administration, the tissue origin of MSCs and also the species from which they derive. 58, [84] [85] [86] For instance, the infusion of MSCs in some mouse models of acute GvHD may fail to prevent the development of the disease, although they can efficiently suppress lymphocyte proliferation in vitro. 84 To be effective, MSCs must be administered in multiple doses at weekly intervals, as shown by studies using human cord bloodderived MSCs to prevent GvHD caused by the injection of human T cells in NOD/SCID mice. 85 By contrast, in the same model, MSC administration either exactly at the time of the lymphocyte infusion or at GvHD onset is completely useless. 85 Further kinetics studies showed that MSCs may significantly prevent GvHD only if they are injected at day þ 2 or þ 20, when the concentration of IFN-g, and probably of other inflammatory cytokines, is significantly high to permit the in vivo licensing of MSCs, but the tissue damage is not too severe yet. 70 By using adipose tissue-derived MSCs, GvHD prevention can be obtained in mice only when MSCs are repeatedly administered at days 0, þ 7 and þ 14, but not later (at days þ 14, þ 21 and þ 28). 87 Similar results are achievable in patients: acute (and, likewise, chronic) GvHD cannot be prevented if MSCs are administered at the time of hematopoietic stem cell transplant, but it can be controlled by repeated MSC infusion (one to five doses) once the symptoms appear. 81 The importance of the timing of MSC engagement is shown in other disease models as well, such as experimental autoimmune encephalomyelitis, the mouse model of multiple sclerosis. 88 Bone marrow-derived MSCs are effective in modulating the signs of experimental autoimmune encephalomyelitis only when they are administered at disease onset (days þ 3 and þ 8), but they are completely useless after disease stabilization (days þ 10 and þ 15). 88 Adipose tissue-derived MSCs may prevent the onset of the disease by using similar administration schedules (days þ 3 and þ 8); however, they may also ameliorate the severity of the neurological signs after disease stabilization. 89 One explanation for this important difference is that adipose tissue-derived MSCs may pass through the hematoencephalic barrier and therefore migrate into the inflamed spinal cord, as they express VLA-4 (a4b1) integrins by which they interact with vascular cell adhesion molecule-1-positive endothelial cells and release anti-inflammatory cytokines, such as IL-10, probably as a consequence of local MSC activation and licensing. 89 The timing of MSC administration may be important also for their antiapoptotic and supporting properties toward neoplastic cells, [51] [52] [53] as well as for their inhibitory effect toward the specific immunity against tumor cells. 26, 90 Systemically infused MSCs show a small capability of long-term engraftment, 91 but they may survive and proliferate in presence of cycling tumor cells, thus becoming intra-tumor stromal fibroblasts, 92 competing with the local mesenchymal cell precursors, 93 and promoting the metastatic dissemination of primary tumors. 53 When co-administered with Sp6 neoplastic plasma cells, MSCs of different origin (bone marrow, spleen, thymus) dramatically enhance the growth kinetics and the resistance to specific antitumor immunity of the developing tumors, even in mice specifically immunized against Sp6 and refractory to tumor engraftment. 26 This supportive property toward cancer cells is also shared by adipose-derived MSCs. 94 It is a common feature of many cancers that the presence of inflammation and stromadependent wound-repair-like processes is not associated with tumor cell elimination, but rather with tumor growth enhancement and worse prognosis; [95] [96] [97] different kinds of stromaderived trophic factors, such as vascular endothelial growth factor, SDF-1, hepatocyte growth factor and IL-6, are involved in this phenomenon, 94, [98] [99] [100] whose release may be induced by the inflammatory cytokine milieu, mainly produced by tumorinfiltrating macrophages. 63, 64, 95, 101 Thus, local licensing of the mesenchymal progenitors, as well as MSCs administered and then incorporated in the tumor microenviroment, may eventually contribute to tumor development and the onset of the 'immunological sanctuary' that prevents tumor cells from being eliminated by immune effector cells. On this basis, many attempts have been made to overcome the stromal support to tumors by engineering MSCs with genes encoding active molecules, such as IFN-b, IFN-a and TRAIL, that can specifically target cancer cell proliferation, reduce the immune-regulatory properties of MSCs and eventually enhance the antitumor immune response.
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Conclusions
The well-characterized and broad inhibitory functions are not constitutively expressed by MSCs, which normally have supportive and antiapoptotic properties toward different cell types and may have, under certain conditions, APC activity. MSCs need to be 'primed' by inflammatory cytokines to become immunosuppressive; however, the final behavior of MSCs depends on different factors with opposite effects, leading to functional polarization toward the inhibitory rather than the pro-inflammatory phenotype. The concentration and the duration of the stimulus, as well as the nature of the danger signal involved, seem to have an important role in MSC polarization. Very often, in vitro data are contradictory and reciprocally not comparable, as they are based on MSCs of different origin, different experimental read-out, different animal models and variable concentrations of the cytokines used for MSC activation; concentrations that can be hardly reached in vivo in the microenviroments where MSCs reside. Thus, it is quite difficult to foresee precisely the final effects of MSCs once they are injected in vivo and reach inflamed tissues, where microenviromental cellular and soluble factors have a pivotal polarizing role. However, experimental evidence of the importance of administration timing suggests that accurate characterization of the inflammatory microenvironment related to a specific disease represents a prerequisite for the therapeutic use of MSCs. Acute inflammation seems to be more modifiable than the chronic phase, and that is one of the major criteria for patient selection. In addition, MSC administration in the presence of early inflammatory signs, rather than as a prophylactic regimen, seems to better guarantee the achievement of in vivo immunosuppressive activity, thus avoiding lack of clinical effect when the disease, already established, becomes completely insensitive to the effect of the MSCs. Finally, co-existence of tumors or previous diagnosis of neoplastic diseases should be always considered as exclusion criteria for the enrolment of patients in MSC systemic administration protocols.
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